Skip to main content
. 2020 Feb 18;94(7):e687–e698. doi: 10.1212/WNL.0000000000008861

Figure 3. Changes in plasma biomarkers of nuclear factor erythroid 2-like 2 (Nrf2) induction in patients with mitochondrial myopathy.

Figure 3

Changes in biomarkers of Nrf2 induction in patients with mitochondrial myopathy from baseline to after 4 weeks of treatment with a range of doses of omaveloxolone (Omav, 38 participants) and placebo (0 mg, 13 participants). (A) Alanine transaminase (ALT). (B) Aspartate transaminase (AST). (C) Ferritin. (D) γ-Glutamyl transferase (GGT). Presented are mean % change with SE bars after 4 weeks treatment vs baseline.